Study of Metformin to reduce Cerebrovascular Dysfunction in South African patients with HIV and Metabolic Syndrome: A Phase II Pilot Trial. SMART
The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Funding Fogarty Program
Global Brain Disorders Research
Project Information in NIH RePORTER
Study of Metformin to reduce Cerebrovascular Dysfunction in South African patients with HIV and Metabolic Syndrome: A Phase II Pilot Trial. SMART
Principal Institution
Stellenbosch University Tygerberg Campus
Principal Investigator(s) (PI)
Decloedt, Eric Hermann; Schifitto, Giovanni
Project Contact Information
Email:
ericdecloedt@sun.ac.za
Year(s) Awarded
2021–2023
Country
South Africa
Project Description
Metabolic syndrome is a constellation of risk factors for cardiovascular disease and type 2 diabetes mellitus which frequently occur together. Data is emerging suggesting metabolic syndrome causes brain disease by contributing to blood vessel damage and inflammation. People living with HIV (PLWH) are at high risk and we will perform a pilot study of the well-known type 2 diabetes drug metformin to treat this blood vessel damage and inflammation in PLWH.
Related World Regions / Countries
Related Global Health Research Topics